72 Participants Needed

REGN7041 for Uveitis

(TITAN Trial)

Recruiting at 1 trial location
CT
Overseen ByClinical Trials Administrator
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Regeneron Pharmaceuticals
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection.

The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug

* How much study drug is in the blood and the fluid in the eye at different times

* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Who Is on the Research Team?

CT

Clinical Trial Management

Principal Investigator

Regeneron Pharmaceuticals

Are You a Good Fit for This Trial?

Adults with active non-infectious uveitis, which is inflammation inside the eye without infection. Participants must have a specific level of visual acuity, meaning their sight isn't too good or too poor as measured by standard eye tests.

Inclusion Criteria

Key
My best vision with glasses is worse than 20/50 but better than 20/630.
My vision is worse than 20/32 but better than 20/630.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • REGN7041

Trial Overview

The trial is testing REGN7041, an experimental drug for reducing eye inflammation in uveitis patients. It's the first time this drug is being used in humans and will assess safety, tolerability, side effects, how much of the drug stays in blood and eye fluid over time, and if the body creates antibodies against it.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Sequential Single Ascending Dose CohortsExperimental Treatment1 Intervention
Group II: Sequential Multiple Ascending Dose CohortsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Regeneron Pharmaceuticals

Lead Sponsor

Trials
690
Recruited
948,000+
Founded
1988
Headquarters
Tarrytown, USA
Known For
Precision medicine
Top Products
Dupixent, EYLEA, Libtayo, Praluent
Leonard Schleifer profile image

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos profile image

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School